Loss of PKCα increases arterial medial calcification in a uremic mouse model of chronic kidney disease

J Borland, Samantha; Facchi, Cecilia; Behnsen, Julia; Adamson, Antony; E Humphreys, Neil; J Withers, Philip; J Sherratt, Michael; E Francis, Sheila; Brennan, Keith; Ashton, Nick; E Canfield, Ann

Abstract

Arterial medial calcification is an independent risk factor for mortality in chronic kidney disease. We previously reported that knock-down of PKCα expression increases high phosphate-induced mineral deposition by vascular smooth muscle cells in vitro. This new study tests the hypothesis that PKCα regulates uremia-induced medial calcification in vivo. Female wild-type and PKCα−/− mice underwent a two-stage subtotal nephrectomy and were fed a high phosphate diet for 8 weeks. X-ray micro computed tomography demonstrated that uremia-induced medial calcification was increased in the abdominal aorta and aortic arch of PKCα−/− mice compared to wild-types. Blood urea nitrogen was also increased in PKCα−/− mice compared to wild-types; there was no correlation between blood urea nitrogen and calcification in PKCα−/− mice. Phosphorylated SMAD2 immunostaining was detected in calcified aortic arches from uremic PKCα−/− mice; the osteogenic marker Runx2 was also detected in these areas. No phosphorylated SMAD2 staining were detected in calcified arches from uremic wild-types. PKCα knock-down increased TGF-β1-induced SMAD2 phosphorylation in vascular smooth muscle cells in vitro, whereas the PKCα activator prostratin decreased SMAD2 phosphorylation. In conclusion, loss of PKCα increases uremia-induced medial calcification. The PKCα/TGF-β signaling axis could therefore represent a new therapeutic target for arterial medial calcification in chronic kidney disease.

• Working Paper Type: Working Paper
• Deposit Date: Dec 19, 2024